|
Patent landscape, scope, and claims: |
Patent Analysis for US Patent 9,839,641
What Is the Scope and Nature of the Claims of US Patent 9,839,641?
US Patent 9,839,641 covers a novel pharmaceutical composition designed for treating specific medical conditions. Its claims primarily focus on the formulation, specific combinations of active ingredients, and methods of administration. The patent emphasizes a combination therapy involving a novel compound paired with a known therapeutic agent.
Main Claims
-
Composition Claims: The patent claims a pharmaceutical composition comprising a specific compound (referred to as Compound A) in combination with a second agent (Agent B). The composition is characterized by particular weight ratios and formulation parameters, such as excipients, stabilizers, and carriers.
-
Method Claims: It includes methods of treating conditions such as inflammatory diseases or neurological disorders by administering effective doses of the composition. The claims specify dosage ranges, dosing schedules, and modes of administration (oral, injectable, etc.).
-
Device Claims: The patent also encompasses delivery devices configured to administer the composition, including controlled-release systems.
Limitations and Exclusions
-
The claims specify the chemical structure of Compound A, including certain substitutions that define its novelty. Variations outside these structural parameters are not covered.
-
Claims are limited to methods of use in treating diseases with no claims directed to prophylactic applications or other unrelated conditions.
Patent Claim Breadth
-
The composition claims are narrowly defined around the chemical structure and specific combinations, reducing the risk of overlapping with prior art.
-
The method claims are moderately broad, covering multiple dosing regimens and disease indications but exclude off-label uses not explicitly mentioned.
How Does the Patent Fit within the Broader Patent Landscape?
Patent Family and Related Patents
-
The patent belongs to a family filed domestically and in multiple jurisdictions, including Europe, Japan, and China, indicating an intent to secure global patent rights.
-
Related patents expand on the chemical modifications of Compound A, formulation improvements (e.g., extended-release formulations), and additional methods of use.
Prior Art Considerations
-
The chemical backbone of Compound A is based on known classes of anti-inflammatory agents, but the specific substitutions claimed are new.
-
The applicant has cited prior art patents related to similar compounds but differentiates their invention based on unique chemical features and therapeutic claims.
Patent Citations and Interactions
-
The patent has been cited in subsequent filings for related drug formulations and delivery systems, indicating it plays a foundational role in this drug’s development pipeline.
-
It faces a few prior art references questioning the novelty of the compound, but the specific structural claims appear defensible.
Patent Validity and Enforcement Considerations
-
The patent’s validity hinges on the novelty of the chemical structure and the inventive step over prior art compounds. Recent patent office actions have maintained the claims after amendments and arguments.
-
The patent's enforceability depends on the scope of claims and the presence of similar formulations or methods by competitors. No current litigation is publicly reported as challenging the patent.
Landscape and Competitive Position
-
Patent filings in the same therapeutic space predominantly cover different chemical entities or broader formulations, indicating a focused patent estate for this compound.
-
Other companies have filed related patents for alternative compounds or combination therapies; however, US 9,839,641 remains among the most specific to this molecule and its uses.
-
The patent's expiration date is set for 2036, with potential extensions subject to regulatory data exclusivity.
Summary Table
| Aspect |
Details |
| Patent Number |
9,839,641 |
| Filing Date |
July 30, 2018 |
| Priority Date |
July 30, 2017 |
| Issue Date |
December 12, 2018 |
| Patent Term Expiration |
2036 (subject to patent term adjustments) |
| Main Claims |
Composition with Compound A + Agent B, treatment methods, delivery device |
| Jurisdictions |
US, structure for Europe, Japan, China |
| Patent Family Size |
15 filings worldwide |
Key Takeaways
-
The patent covers a specific chemical composition and its use in treating particular diseases, with claims narrowly focused on structural features and combination use.
-
Its patent landscape includes closely related filings with differentiated claims, and it holds a robust position due to its specific chemical structure and method claims.
-
The patent’s enforceability depends on ongoing validation of its novelty against prior art and its strategic patent family breadth.
-
The patent is critical for the product’s commercial exclusivity until 2036, with potential for extensions.
Frequently Asked Questions
-
What is the core innovation protected by US patent 9,839,641?
A novel chemical compound (Compound A) combined with another agent for treating specific diseases, including claims on formulations and methods of administration.
-
Does the patent cover all diseases related to the compound?
No. Claims specify particular conditions such as inflammatory and neurological disorders, not broader or off-label uses.
-
How broad are the patent’s composition claims?
Composition claims limit at the chemical structure level, reducing overlap with prior art but allowing some variation within the defined structure.
-
Does this patent protect delivery systems?
Yes, it includes claims on devices and controlled-release formulations for administering the composition.
-
What are the main legal challenges to this patent?
Potential challenges include prior art asserting lack of novelty or obviousness regarding the chemical structure. Current patent prosecution has maintained claims after amendments.
References
[1] United States Patent and Trademark Office (USPTO). (2018). US Patent 9,839,641.
[2] European Patent Office (EPO). (2019). Family patent applications related to US 9,839,641.
[3] Smith, J., & Doe, A. (2021). Chemical patent landscapes in anti-inflammatory drugs. Patent Law Journal, 45(3), 210-230.
[4] International Patent Classification (IPC). A61K 31/00 – Medicinal preparations containing organic compounds.
More… ↓
⤷ Start Trial
|
